Stockreport

Baudax Bio Announces U.S. Availability of ANJESO™ (meloxicam) Injection for the Management of Moderate to Severe Pain

Baudax Bio, Inc.  (BXRX) 
PDF ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing Full Commercial Launch Expected to Commence by June 2020 MALVER [Read more]